EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 × 2 factorial design, randomised controlled comparison with simvastatin

Imran B Chaudhry, Muhammad Omair Husain, Ameer B Khoso, Tayyeba Kiran, Muhammad Ishrat Husain, Inti Qurashi, Raza Ur Rahman, Nasir Mehmood, Richard Drake, Nusrat Husain, Bill Deakin iD

Journal of Psychopharmacology · 2024

DOI: 10.1177/02698811241267836 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Psychopharmacology, 2024. Verfasst von Imran B Chaudhry und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Dow University of Health Sciences, Karachi, Pakistan. Hauptthemen laut MEDLINE: Ondansetron, Schizophrenia, Simvastatin, Antipsychotic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stanley Medical Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Variable benefits have been reported from the adjunctive use of simvastatin and the 5HT3 receptor antagonist, ondansetron, in patients with schizophrenia. We investigated their independent efficacy and possible synergy to improve negative symptoms of schizophrenia within a single trial.

Methods

A 6-month, randomised, double-blind, placebo-controlled trial with a 4-arm, 2 × 2 factorial design, in three centres in Pakistan. In total, 303 people with stable treated schizophrenia aged 18–65 were randomly allocated to add-on ondansetron, simvastatin, both or neither. The primary outcome was a Positive and Negative Syndrome Scale (PANSS) negative score at 3 and 6 months.

Results

Mixed model analysis and analysis of covariance revealed no main effects of simvastatin or ondansetron but a significant negative interaction between them ( p = 0.03); when given alone, both drugs significantly reduced negative symptoms compared to placebo but they were ineffective in combination. Individual treatment effects versus placebo were −1.9 points (95%CIs −3.23, −0.49; p = 0.01) for simvastatin and −1.6 points for ondansetron (95%CIs −3.00, −0.14; p = 0.03). Combined treatment significantly increased depression and side effects. In those with less than the median 5 years of treatment, ondansetron improved all PANSS subscales, global functioning measures and verbal learning and fluency, whereas simvastatin did not.

Conclusion

Small improvement in negative symptoms on simvastatin and ondansetron individually are not synergistic in combination in treating negative symptoms of schizophrenia. Ondansetron showed broad efficacy in patients on stable antipsychotic treatment within 5 years of illness. The findings suggest that ondansetron should be evaluated in patients at risk of psychosis or early in treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OndansetronSchizophreniaSimvastatinAntipsychotic AgentsDrug Therapy, CombinationCognitionSerotonin 5-HT3 Receptor AntagonistsHumansDouble-Blind MethodAdultMaleFemaleMiddle AgedYoung AdultAdolescentAgedSchizophrenic PsychologyTreatment OutcomePakistan

Stichwörter der Autor:innen

Ondansetronclinical trialnegative symptomsschizophreniasimvastatin

Substanzen

OndansetronSimvastatinAntipsychotic AgentsSerotonin 5-HT3 Receptor Antagonists

Autor:innen und Institutionen

  • Department of Psychiatry, Dow University of Health Sciences, Karachi, Pakistan.
  • Ziauddin University Hospital, Karachi, Pakistan.
  • Pakistan Institute of Living and Learning, Karachi, Pakistan.
  • Division of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
  • Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
  • Temerty Faculty of Medicine, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: Bill Deakin

Förderung

  • Stanley Medical Research Institute

Zitieren

APA

Chaudhry, I. B., Husain, M. O., Khoso, A. B., Kiran, T., Husain, M. I., Qurashi, I., Rahman, R. U., Mehmood, N., Drake, R., Husain, N., & Deakin, B. (2024). Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 × 2 factorial design, randomised controlled comparison with simvastatin. Journal of Psychopharmacology. https://doi.org/10.1177/02698811241267836

Vancouver

Chaudhry IB, Husain MO, Khoso AB, Kiran T, Husain MI, Qurashi I, et al. Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 × 2 factorial design, randomised controlled comparison with simvastatin. Journal of Psychopharmacology. 2024. doi:10.1177/02698811241267836

BibTeX
@article{Chaudhry2024,
  author = {Chaudhry, Imran B and Husain, Muhammad Omair and Khoso, Ameer B and Kiran, Tayyeba and Husain, Muhammad Ishrat and Qurashi, Inti and Rahman, Raza Ur and Mehmood, Nasir and Drake, Richard and Husain, Nusrat and Deakin, Bill},
  title = {Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 × 2 factorial design, randomised controlled comparison with simvastatin},
  journal = {Journal of Psychopharmacology},
  year = {2024},
  doi = {10.1177/02698811241267836}
}
Kostenlos starten →